1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsA 24-month enterprise growth program supporting young entrepreneurs building ventures in agrifood, nutrition, and sustainability. It focuses on inclusive entrepreneurship and expanding opportunities for underrepresented groups.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Young entrepreneurs building ventures in agrifood, nutrition, and sustainability. Women, persons with disabilities, and internally displaced persons are strongly encouraged to apply. Confirm the full requirements in the official notice before applying.
The current listing shows not specified (24-month program). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for AYA Accelerator 2026 are due September 30, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
AYA Accelerator 2026 is funded by AYA Accelerator. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articleThe Council on Foundations opened a Working Across Differences Accelerator for community foundations — a $20,000 planning grant, up to $45,000 in follow-on funding, and a November 2026 cohort start, backed by Mott and the Walmart Foundation. The dollar figures are small and the strategic value is not. Here is how to read a two-stage cohort program, and why the vocabulary this fund chose is itself the lesson.
Read articleThe EDA's May 11 NOFO will award 5-8 grants of $1M-$8M for AI workforce training — but only to employer-led sectoral partnerships, not standalone training providers. With a 60% federal cap and a 24-36 month performance period, the design favors regional coalitions over universities. Here is how to assemble a winning application.
Read article